Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $431.78M
• Dividend Yield: N/A
• Average Volume (3M): 3.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: 0.37%
• EPS Growth: -20.49%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 54
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 654,216,060
• 10 Day Avg. Volume: 3,274,592
• 30 Day Avg. Volume: 3,184,532
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 108.51
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.70
• Price Target Upside: 129.73% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

Senseonics Holdings' overall stock score reflects its financial challenges characterized by continuous losses and high leverage, countered slightly by technical improvements and strategic growth initiatives. Despite promising advancements with the Eversense 365 and strong partnerships, the company's valuation and financial health remain critical concerns, resulting in a lower overall score.

Positive Factors

Market Expansion

Physicians expect the US CGM category to expand 20%+, which is ahead of the estimated forecast from market leaders.

Product Approval

Eversense 365 iCGM secured FDA clearance and was launched via its marketing partnership with Ascensia Diabetes Care.

Negative Factors

Competitive Challenges

There is skepticism about SENS's ability to gain traction in the CGM market against established competitors, despite the 365-day indication.

Financial Concerns

SENS shares are considered expensive as they trade at a high multiple of projected sales and the company is burning cash, increasing the risk of dilution.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics Holdings generates revenue primarily through the sale of its Eversense CGM system and related products. The company's revenue model involves direct sales to healthcare providers and distribution partnerships that facilitate the availability of its CGM systems in various markets. Key revenue streams include the initial purchase of the CGM system components and ongoing sales of consumables like sensors and transmitters required for continuous monitoring. Significant partnerships with healthcare providers, distribution partners, and insurers also contribute to its earnings by expanding market reach and facilitating reimbursement processes for patients.

Senseonics Holdings Financial Statement Overview

Summary

Senseonics Holdings faces significant financial challenges, including continuous losses and high leverage. While revenue shows slight growth, profitability remains a major concern with negative margins across the board. The balance sheet's negative equity and high debt levels indicate financial instability, and the cash flow statement reflects ongoing liquidity issues. The company must focus on improving operational efficiency and financial health to enhance its financial standing.

Income Statement

Senseonics Holdings has shown minimal revenue growth with a slight increase in total revenue from $22.39M in 2023 to $22.47M TTM. However, profitability metrics are concerning: Gross Profit Margin is low at 2.37%, and both EBIT and EBITDA margins are negative, indicating the company is operating at a significant loss. The Net Profit Margin is also negative, reflecting ongoing challenges in achieving profitability.

Balance Sheet

The company has a notably high Debt-to-Equity ratio due to negative equity, suggesting financial instability. The Return on Equity is not applicable due to negative equity. Additionally, the equity ratio is inverted due to negative stockholders' equity, highlighting potential financial distress. The balance sheet reveals a capital structure heavily reliant on debt.

Cash Flow

Operating cash flow remains negative, but there is a slight improvement in free cash flow from -$70.51M in 2023 to -$62.70M TTM. Operating Cash Flow to Net Income Ratio is not favorable at 0.77, indicating cash flow issues. However, financing activities have provided some cash influx, albeit this may not be sustainable long-term.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
22.39M	16.39M	13.68M	4.95M	21.30M
	Gross Profit
3.09M	2.73M	-811.00K	-17.37M	-19.45M
	EBIT
-75.60M	-68.63M	-57.18M	-79.13M	-130.66M
	EBITDA
-48.01M	161.81M	-284.51M	-157.86M	-99.41M
	Net Income Common Stockholders
-60.39M	142.12M	-317.78M	-191.02M	-126.23M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
109.46M	144.01M	129.91M	18.00M	95.94M
	Total Assets
138.22M	177.67M	198.93M	35.92M	132.60M
	Total Debt
47.78M	74.65M	63.30M	62.70M	119.22M
	Net Debt
-27.93M	38.86M	29.84M	44.69M	23.29M
	Total Liabilities
64.77M	180.25M	384.46M	180.00M	141.45M
	Stockholders Equity
73.45M	-2.58M	-185.53M	-144.08M	-8.85M
Cash Flow		Free Cash Flow
-70.51M	-66.62M	-56.29M	-67.60M	-137.09M
	Operating Cash Flow
-70.16M	-66.31M	-56.08M	-67.42M	-136.05M
	Investing Cash Flow
89.71M	26.88M	-148.75M	-181.00K	-1.04M
	Financing Cash Flow
20.37M	41.76M	220.08M	-10.13M	96.24M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Positive. The current price of 0.74 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.67, and above the 200-day MA of 0.55, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 56.67 is Neutral, neither overbought nor oversold. The STOCH value of 35.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	76 Outperform	$32.00B	60.26	23.72%	―	9.11%	-17.87%
LIVN	63 Neutral	$1.91B	30.62	-19.69%	―	7.97%	-592.40%
OM	54 Neutral	$204.51M	―	-86.53%	―	-7.84%	42.34%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
TNDM	49 Neutral	$1.42B	―	-92.31%	―	27.65%	-28.22%
SENS	41 Neutral	$431.78M	―	-166.29%	―	0.37%	-20.49%
NNOX	39 Underperform	$314.35M	―	-27.83%	―	13.91%	15.46%

Senseonics Holdings Corporate Events

Senseonics Holdings Expands with Innovative Diabetes Solutions

Senseonics Holdings, Inc. is revolutionizing diabetes management with the Eversense® 365 Continuous Glucose Monitoring (CGM) System, the only fully implantable CGM approved for a year-long duration. Recently cleared by the FDA, the Eversense® 365 addresses key complaints of comfort and accuracy, and targets the underpenetrated $20 billion U.S. CGM market. Partnering with Ascensia Diabetes Care and Mercy Health, Senseonics is poised to expand its market presence, while developing next-gen devices like the self-powering Gemini System and the Freedom System, enhancing user convenience and connectivity.